Nicholas Cross

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/230047/publications.pdf

Version: 2024-02-01

286 papers	32,163 citations	4658 85 h-index	4645 170 g-index
287 all docs	287 docs citations	287 times ranked	21264 citing authors

#	Article	IF	Citations
1	A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome. New England Journal of Medicine, 2003, 348, 1201-1214.	27.0	1,655
2	Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood, 2013, 122, 3616-3627.	1.4	1,562
3	SomaticCALRMutations in Myeloproliferative Neoplasms with NonmutatedJAK2. New England Journal of Medicine, 2013, 369, 2391-2405.	27.0	1,556
4	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 2006, 108, 28-37.	1.4	1,117
5	Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics, 2010, 42, 722-726.	21.4	1,034
6	Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 2002, 16, 2190-2196.	7.2	839
7	Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia. New England Journal of Medicine, 2005, 353, 33-45.	27.0	838
8	Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 2005, 106, 2162-2168.	1.4	798
9	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	7.2	653
10	Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta. New England Journal of Medicine, 2002, 347, 481-487.	27.0	623
11	Aberrations of EZH2 in Cancer. Clinical Cancer Research, 2011, 17, 2613-2618.	7.0	503
12	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 2011, 118, 1208-1215.	1.4	486
13	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology, 2013, 31, 2428-2436.	1.6	462
14	CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood, 2003, 102, 3093-3096.	1.4	368
15	JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nature Genetics, 2009, 41, 446-449.	21.4	365
16	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nature Genetics, 2013, 45, 18-24.	21.4	359
17	Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood, 2008, 112, 3330-3338.	1.4	350
18	Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood, 2009, 113, 6182-6192.	1.4	349

#	Article	IF	Citations
19	Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia, 2012, 26, 2172-2175.	7.2	339
20	Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nature Genetics, 2014, 46, 624-628.	21.4	320
21	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood, 2006, 108, 1497-1503.	1.4	317
22	Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia, 2015, 29, 999-1003.	7.2	280
23	The t(8;9)(p22;p24) Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM1 to JAK2. Cancer Research, 2005, 65, 2662-2667.	0.9	269
24	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 2014, 28, 1804-1810.	7.2	263
25	DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia. New England Journal of Medicine, 2005, 352, 1529-1538.	27.0	262
26	Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia, 1999, 13, 1825-1832.	7.2	255
27	A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood, 2001, 98, 1264-1267.	1.4	245
28	Imatinib for systemic mast-cell disease. Lancet, The, 2003, 362, 535-537.	13.7	242
29	EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 2011, 118, 5227-5234.	1.4	242
30	KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia, 2015, 29, 1223-1232.	7.2	229
31	Comprehensive mutational profiling in advanced systemic mastocytosis. Blood, 2013, 122, 2460-2466.	1.4	222
32	The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of <i>FGFR1</i>. Acta Haematologica, 2002, 107, 101-107.	1.4	220
33	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 2012, 119, 3211-3218.	1.4	220
34	Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood, 2003, 101, 3391-3397.	1.4	206
35	Harmonization of molecular monitoring of CML therapy in Europe. Leukemia, 2009, 23, 1957-1963.	7.2	196
36	Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nature Communications, 2015, 6, 5901.	12.8	196

#	Article	IF	Citations
37	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRAâ€“positive chronic eosinophilic leukemia. Blood, 2007, 109, 4635-4640.	1.4	195
38	MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell, 2003, 3, 259-271.	16.8	192
39	The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood, 2013, 121, 468-475.	1.4	190
40	The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood, 2001, 98, 3778-3783.	1.4	189
41	Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis. Leukemia, 2016, 30, 136-143.	7.2	185
42	Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia, 2006, 20, 1925-1930.	7.2	184
43	Myeloproliferative Disorders with Translocations of Chromosome 5q31â€“35: Role of the Platelet-Derived Growth Factor Receptor Beta. Acta Haematologica, 2002, 107, 113-122.	1.4	170
44	Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia, 2007, 21, 1183-1188.	7.2	170
45	Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood, 2012, 119, 1208-1213.	1.4	162
46	Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. British Journal of Cancer, 2004, 91, 1155-1159.	6.4	161
47	Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graftâ€versusâ€host disease and relapse. British Journal of Haematology, 1993, 84, 67-74.	2.5	159
48	Durable responses to imatinib in patients with PDGFRB fusion geneâ€“positive and BCR-ABLâ€“negative chronic myeloproliferative disorders. Blood, 2007, 109, 61-64.	1.4	156
49	Early detection of BCR-ABL transcripts by quantitative reverse transcriptaseâ€“polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 2001, 97, 1560-1565.	1.4	154
50	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood, 2015, 125, 1857-1865.	1.4	153
51	Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell, 2004, 5, 287-298.	16.8	145
52	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nature Communications, 2015, 6, 6691.	12.8	145
53	A potent inhibitor ofTaqpolymerase copurifies with human genomic DNA. Nucleic Acids Research, 1988, 16, 10355-10355.	14.5	143
54	The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Annals of Hematology, 2014, 93, 81-88.	1.8	142

#	Article	IF	Citations
55	Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia, 2006, 20, 1610-1617.	7.2	141
56	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood, 2010, 116, e111-e117.	1.4	141
57	The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Human Molecular Genetics, 2002, 11, 1391-1397.	2.9	139
58	Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia, 2004, 18, 962-966.	7.2	137
59	Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia, 2015, 29, 1115-1122.	7.2	134
60	Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood, 2007, 110, 3291-3300.	1.4	133
61	Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia, 2011, 25, 877-879.	7.2	131
62	A novel K509I mutation of KIT identified in familial mastocytosisâ€"in vitro and in vivo responsiveness to imatinib therapy. Leukemia Research, 2006, 30, 373-378.	0.8	129
63	Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome â€“ a phaseâ€ study. British Journal of Haematology, 2008, 143, 707-715.	2.5	128
64	Molecular analysis of aldolase B genes in hereditary fructose intolerance. Lancet, The, 1990, 335, 306-309.	13.7	127
65	Oncogenic protein tyrosine kinases. Cellular and Molecular Life Sciences, 2004, 61, 2912-2923.	5.4	126
66	Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia, 2002, 16, 1207-1212.	7.2	124
67	Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia, 2006, 20, 827-832.	7.2	122
68	Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood, 2006, 107, 4171-4176.	1.4	119
69	Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood, 2014, 123, 3574-3577.	1.4	118
70	Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood, 2006, 107, 3339-3341.	1.4	113
71	Guideline for the investigation and management of eosinophilia. British Journal of Haematology, 2017, 176, 553-572.	2.5	110
72	Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia, 2000, 14, 998-1005.	7.2	105

#	Article	IF	Citations
73	Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. Cell, 1988, 53, 881-885.	28.9	98
74	An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica, 2015, 100, 1117-1130.	3.5	97
75	Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood, 2017, 130, 137-145.	1.4	97
76	Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia, 2013, 27, 2032-2039.	7.2	96
77	Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia, 2020, 34, 2660-2672.	7.2	96
78	Accurate Detection and Quantitation of Heteroplasmic Mitochondrial Point Mutations by Pyrosequencing. Genetic Testing and Molecular Biomarkers, 2005, 9, 190-199.	1.7	94
79	Guidelines for the measurement of BCRâ€ABL1 transcripts in chronic myeloid leukaemia. British Journal of Haematology, 2011, 153, 179-190.	2.5	94
80	The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood, 2010, 115, 4517-4523.	1.4	93
81	Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes and Cancer, 2001, 32, 155-163.	2.8	91
82	Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood, 2007, 110, 3729-3734.	1.4	91
83	Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia, 2016, 30, 57-64.	7.2	91
84	Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome. Genes Chromosomes and Cancer, 2004, 40, 78-83.	2.8	89
85	Type 5 acid phosphatase. Sequence, expression and chromosomal localization of a differentiation-associated protein of the human macrophage. FEBS Journal, 1990, 189, 287-293.	0.2	88
86	Novel translocations that disrupt the plateletâ€derived growth factor receptor Î² (PDGFRB) gene in BCRâ€“ABLâ€negative chronic myeloproliferative disorders. British Journal of Haematology, 2003, 120, 251-256.	2.5	87
87	Methylation-Sensitive High-Resolution Melting-Curve Analysis of the SNRPN Gene as a Diagnostic Screen for Prader-Willi and Angelman Syndromes. Clinical Chemistry, 2007, 53, 1960-1962.	3.2	87
88	Molecular diagnosis of the myeloproliferative neoplasms: <scp>UK</scp> guidelines for the detection of <scp>JAK</scp>2 <scp>V</scp>617<scp>F</scp> and other relevant mutations. British Journal of Haematology, 2013, 160, 25-34.	2.5	87
89	TELâ€AML1 fusion in acute lymphoblastic leukaemia of adults. British Journal of Haematology, 1996, 95, 673-677.	2.5	86
90	The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia, 2005, 19, 1005-1009.	7.2	85

#	Article	IF	Citations
91	Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Practice and Research in Clinical Haematology, 2009, 22, 355-365.	1.7	85
92	Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor Â gene. Haematologica, 2007, 92, 163-169.	3.5	84
93	The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica, 2010, 95, 1221-1225.	3.5	84
94	The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica, 2017, 102, 1035-1043.	3.5	84
95	Two novel imatinibâ€responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. British Journal of Haematology, 2007, 138, 77-81.	2.5	79
96	In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood, 2010, 116, 1329-1335.	1.4	78
97	Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood, 2011, 117, 2935-2943.	1.4	76
98	Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-Î±. British Journal of Haematology, 1995, 91, 126-131.	2.5	75
99	Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. British Journal of Haematology, 2009, 144, 904-908.	2.5	75
100	Response of ETV6-FLT3â€“positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood, 2011, 118, 2239-2242.	1.4	75
101	p53-Binding Protein 1 Is Fused to the Platelet-Derived Growth Factor Receptor Î² in a Patient with a t(5;15)(q33;q22) and an Imatinib-Responsive Eosinophilic Myeloproliferative Disorder. Cancer Research, 2004, 64, 7216-7219.	0.9	74
102	Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Annals of Hematology, 2015, 94, 233-238.	1.8	74
103	Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia, 2005, 19, 1634-1642.	7.2	73
104	Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia, 2016, 30, 2342-2350.	7.2	73
105	The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. British Journal of Haematology, 1997, 99, 945-950.	2.5	72
106	Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2â€PDGFRA fusion gene. Genes Chromosomes and Cancer, 2006, 45, 950-956.	2.8	72
107	Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood, 2007, 110, 1283-1290.	1.4	72
108	Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica, 2010, 95, 738-744.	3.5	72

#	Article	IF	Citations
109	A certified plasmid reference material for the standardisation of BCRâ€“ABL1 mRNA quantification by real-time quantitative PCR. Leukemia, 2015, 29, 369-376.	7.2	72
110	TET2 Mutations Are Associated with Specific 5-Methylcytosine and 5-Hydroxymethylcytosine Profiles in Patients with Chronic Myelomonocytic Leukemia. PLoS ONE, 2012, 7, e31605.	2.5	70
111	Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica, 2013, 98, 103-106.	3.5	70
112	Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. Leukemia, 2005, 19, 245-252.	7.2	69
113	The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. Journal of Clinical Investigation, 2017, 127, 2206-2221.	8.2	69
114	Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica, 2009, 94, 1708-1713.	3.5	68
115	Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplantation, 1998, 21, 1055-1061.	2.4	67
116	NIN, a Gene Encoding a CEP110-Like Centrosomal Protein, Is Fused to PDGFRB in a Patient with a t(5;14)(q33;q24) and an Imatinib-Responsive Myeloproliferative Disorder 1. Cancer Research, 2004, 64, 2673-2676.	0.9	67
117	Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica, 2010, 95, 1473-1480.	3.5	67
118	Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. British Journal of Haematology, 2001, 115, 569-574.	2.5	66
119	Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes and Cancer, 2009, 48, 624-636.	2.8	65
120	Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. Leukemia, 2019, 33, 415-425.	7.2	65
121	Impact ofBCR-ABLmutations on patients with chronic myeloid leukemia. Cell Cycle, 2011, 10, 250-260.	2.6	64
122	Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR. British Journal of Haematology, 1995, 90, 138-146.	2.5	63
123	Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: Results at 4 years. International Journal of Cancer, 2005, 114, 94-100.	5.1	63
124	TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals. Haematologica, 2010, 95, 20-26.	3.5	63
125	Genomics of Myeloproliferative Neoplasms. Journal of Clinical Oncology, 2017, 35, 947-954.	1.6	62
126	Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia, 2013, 27, 2254-2256.	7.2	61

#	Article	IF	Citations
127	Eosinophilic disorders: Molecular pathogenesis, new classification, and modern therapy. Best Practice and Research in Clinical Haematology, 2006, 19, 535-569.	1.7	60
128	Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders. Journal of Molecular Diagnostics, 2007, 9, 272-276.	2.8	60
129	Fibroblast Growth Factor Receptor and Platelet-Derived Growth Factor Receptor Abnormalities in Eosinophilic Myeloproliferative Disorders. Acta Haematologica, 2008, 119, 199-206.	1.4	59
130	Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromosomes and Cancer, 2003, 36, 175-188.	2.8	58
131	Minimal Residual Disease after Bone Marrow Transplant for Chronic Myeloid Leukaemia Detected by the Polymerase Chain Reaction. Leukemia and Lymphoma, 1993, 11, 39-43.	1.3	57
132	A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. British Journal of Haematology, 1994, 86, 683-685.	2.5	56
133	JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leukemia Research, 2011, 35, 177-182.	0.8	56
134	Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. International Journal of Hematology, 2015, 101, 229-242.	1.6	56
135	The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse preâ€mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1. Genes Chromosomes and Cancer, 2008, 47, 379-385.	2.8	55
136	Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia, 2012, 26, 162-164.	7.2	55
137	Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leukemia Research, 2015, 39, 82-87.	0.8	55
138	JAK2 Mutations are present in all cases of polycythemia vera. Leukemia, 2008, 22, 1289-1289.	7.2	53
139	Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia, 2016, 30, 1844-1852.	7.2	51
140	Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. British Journal of Haematology, 1999, 106, 634-643.	2.5	50
141	Consistent Fusion of MOZ and TIF2 in AML with inv(8)(p11q13). Cancer Genetics and Cytogenetics, 1999, 113, 70-72.	1.0	50
142	<scp>KIT</scp><scp>D</scp>816<scp>V</scp> and <scp>JAK</scp>2<scp>V</scp>617<scp>F</scp> mutations are seen recurrently in hypereosinophilia of unknown significance. American Journal of Hematology, 2015, 90, 774-777.	4.1	50
143	Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica, 2008, 93, 1560-1564.	3.5	49
144	Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. Leukemia, 2022, 36, 507-515.	7.2	49

#	Article	IF	Citations
145	Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. The Hematology Journal, 2004, 5, 534-537.	1.4	49
146	An atypical myeloproliferative disorder with t(8;13) (p11;q12): a third case. British Journal of Haematology, 1994, 86, 879-880.	2.5	48
147	The effect of initial molecular profile on response to recombinant interferonâ€Î± (rIFNÎ±) treatment in early myelofibrosis. Cancer, 2017, 123, 2680-2687.	4.1	48
148	Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia. British Journal of Haematology, 2005, 130, 229-232.	2.5	47
149	Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica, 2009, 94, 1024-1028.	3.5	47
150	Isolation and characterization of the genes encoding mouse and human type-5 acid phosphatase. Gene, 1993, 130, 201-207.	2.2	46
151	The influence of INK4 proteins on growth and self-renewal kinetics of hematopoietic progenitor cells. Blood, 2001, 97, 2604-2610.	1.4	46
152	Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. Clinical Chemistry, 2013, 59, 938-948.	3.2	46
153	Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. Haematologica, 2013, 98, 1414-1420.	3.5	46
154	JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?. Leukemia, 2006, 20, 2067-2067.	7.2	45
155	A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Experimental Hematology, 2007, 35, 1723-1727.	0.4	44
156	Critical Role of STAT5 Activation in Transformation Mediated by ZNF198-FGFR1. Journal of Biological Chemistry, 2004, 279, 6666-6673.	3.4	43
157	Analysis of genomic breakpoints in p190 and p210 BCRâ€“ABL indicate distinct mechanisms of formation. Leukemia, 2010, 24, 1742-1750.	7.2	43
158	P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12. Leukemia, 2003, 17, 2097-2100.	7.2	42
159	Impact of isolated germline JAK2V617I mutation on human hematopoiesis. Blood, 2013, 121, 4156-4165.	1.4	42
160	HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. Leukemia, 2021, 35, 3040-3043.	7.2	42
161	JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia, 2006, 20, 534-535.	7.2	41
162	Molecular basis of myelodysplastic/myeloproliferative neoplasms. Haematologica, 2009, 94, 1634-1638.	3.5	41

#	Article	IF	Citations
163	Tsetse fly rDNA: an analysis of structure and sequence. Nucleic Acids Research, 1987, 15, 15-30.	14.5	40
164	Quantification of PMLâ€RARÎ± transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RTâ€PCR for the detection of minimal residual disease and induction of the leukaemiaâ€specific mRNA by alpha interferon. British Journal of Haematology, 1996, 95, 95-101.	2.5	40
165	Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia. British Journal of Haematology, 2011, 153, 43-46.	2.5	40
166	Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. British Journal of Haematology, 2014, 167, 421-423.	2.5	40
167	Myeloproliferative disorders. Best Practice and Research in Clinical Haematology, 2001, 14, 531-551.	1.7	39
168	ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood, 2001, 98, 2879-2880.	1.4	38
169	Idiopathic Hypereosinophilic Syndrome in Children. Journal of Pediatric Hematology/Oncology, 2005, 27, 663-665.	0.6	38
170	Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. Haematologica, 2017, 102, e238-e240.	3.5	38
171	Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. Leukemia, 2019, 33, 1195-1205.	7.2	38
172	A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. British Journal of Haematology, 2020, 191, 171-193.	2.5	38
173	Rarity of microsatellite alterations in acute myeloid leukaemia. British Journal of Cancer, 1996, 74, 255-257.	6.4	37
174	Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity. European Respiratory Journal, 2006, 27, 230-232.	6.7	37
175	Mutations in <scp>SETBP</scp>1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression. British Journal of Haematology, 2013, 163, 235-239.	2.5	37
176	Cytogenetics of chronic myeloid leukaemia. Best Practice and Research in Clinical Haematology, 2001, 14, 553-571.	1.7	36
177	Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. Leukemia, 2021, 35, 2445-2459.	7.2	36
178	BCR-ABL antisense purging in chronic myeloid leukaemia. Lancet, The, 1993, 342, 614.	13.7	35
179	Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions. Leukemia, 2009, 23, 332-339.	7.2	35
180	Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements. Haematologica, 2013, 98, 404-408.	3.5	35

#	Article	IF	Citations
181	Identification of U2AF(35)-dependent exons by RNA-Seq reveals a link between 3â€² splice-site organization and activity of U2AF-related proteins. Nucleic Acids Research, 2015, 43, 3747-3763.	14.5	35
182	Molecular response of CML patients treated with interferonâ€Ì± monitored by quantitative Southern blot analysis. British Journal of Haematology, 1997, 97, 86-93.	2.5	34
183	A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. Leukemia, 2014, 28, 1570-1572.	7.2	34
184	A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. Leukemia, 2007, 21, 1839-1841.	7.2	33
185	Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Haematologica, 2012, 97, 538-542.	3.5	31
186	Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders. Current Drug Targets, 2007, 8, 205-216.	2.1	30
187	International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leukemia Research, 2008, 32, 505-506.	0.8	30
188	A new aldolase B variant, N334K, is a common cause of hereditary fructose intolerance in Yugoslavia. Nucleic Acids Research, 1990, 18, 1925-1925.	14.5	29
189	The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster. Leukemia, 1997, 11, 233-238.	7.2	29
190	Chronic Myeloproliferative Disorders: The Role of Tyrosine Kinases in Pathogenesis, Diagnosis and Therapy. Pathobiology, 2007, 74, 81-88.	3.8	29
191	A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon Â. Haematologica, 2010, 95, 148-152.	3.5	29
192	Activating CBL mutations are associated with a distinct MDS/MPN phenotype. Annals of Hematology, 2012, 91, 1713-1720.	1.8	29
193	Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1585-1596.	2.5	29
194	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia, 2019, 33, 1124-1134.	7.2	29
195	Two patients with novel BCR/ABL fusion transcripts (e8/a2 and e13/a2) resulting from translocation breakpoints within BCR exons. British Journal of Haematology, 1999, 105, 434-436.	2.5	28
196	NUP98-LEDGF fusion and t(9;11) in transformed chronic myeloid leukemia. Leukemia Research, 2005, 29, 1469-1472.	0.8	28
197	Chronic Eosinophilic Leukaemia Presenting with Erythroderma, Mild Eosinophilia and Hyper-IgE: Clinical, Immunological and Cytogenetic Features and Therapeutic Approach. Acta Haematologica, 2002, 107, 108-112.	1.4	27
198	IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. Leukemia, 2011, 25, 178-181.	7.2	27

#	Article	IF	Citations
199	Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophiliaâ€associated myeloproliferative neoplasms. Genes Chromosomes and Cancer, 2015, 54, 762-770.	2.8	27
200	Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation. Annals of Hematology, 2016, 95, 557-562.	1.8	27
201	The severity of FIP1L1â€“PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. Leukemia, 2007, 21, 2428-2432.	7.2	26
202	Atypical mRNA fusions in PMLâ€RARA positive, RARAâ€PML negative acute promyelocytic leukemia. Genes Chromosomes and Cancer, 2010, 49, 471-479.	2.8	26
203	Localization of the 8;13 translocation breakpoint associated with myeloproliferative disease to a 1.5 mbp region of chromosome 13. Genes Chromosomes and Cancer, 1995, 12, 283-287.	2.8	25
204	Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCRâ€FGFR1 gene fusion. Pediatric Blood and Cancer, 2012, 59, 194-196.	1.5	25
205	The future of JAK inhibition in myelofibrosis and beyond. Blood Reviews, 2014, 28, 189-196.	5.7	25
206	Rarity of dominant-negative mutations of the G-CSF receptor in patients with blast crisis of chronic myeloid leukemia or de novo acute leukemia. Leukemia, 1997, 11, 1005-1008.	7.2	24
207	The Genomic Structure of ZNF198 and Location of Breakpoints in the t(8;13) Myeloproliferative Syndrome. Genomics, 1999, 55, 118-121.	2.9	24
208	Simultaneous MLPA-based multiplex point mutation and deletion analysis of the Dystrophin gene. Molecular Biotechnology, 2007, 35, 135-140.	2.4	24
209	Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia, 2008, 22, 1320-1334.	7.2	24
210	JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. Leukemia, 2013, 27, 1763-1767.	7.2	24
211	Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis. Journal of Clinical Oncology, 2022, 40, 1783-1794.	1.6	24
212	The molecular anatomy of the FIP1L1-PDGFRA fusion gene. Leukemia, 2009, 23, 271-278.	7.2	23
213	Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients. Leukemia, 2013, 27, 2105-2107.	7.2	23
214	Identification and functional characterization of imatinibâ€sensitive DTD1â€PDGFRB and CCDC88Câ€PDGFRB fusion genes in eosinophiliaâ€associated myeloid/lymphoid neoplasms. Genes Chromosomes and Cancer, 2014, 53, 411-421.	2.8	23
215	Polymerase chain reaction automated at low cost. Nucleic Acids Research, 1988, 16, 5687-5688.	14.5	22
216	Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels ofBCR-ABL mRNA in chronic myeloid leukaemia. Genes Chromosomes and Cancer, 1995, 13, 110-114.	2.8	22

#	Article	IF	Citations
217	Mutational analysis of the p15 and p16 genes in acute leukaemias. British Journal of Haematology, 1996, 92, 681-683.	2.5	22
218	A novel BCR-ABL fusion gene (e2/1a) in a patient with Philadelphia-positive chronic myelogenous leukaemia and an aggressive clinical course. British Journal of Haematology, 1998, 103, 791-794.	2.5	22
219	Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. Leukemia, 2020, 34, 2113-2124.	7.2	22
220	FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. Leukemia, 2007, 21, 397-402.	7.2	21
221	BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia, 2008, 22, 1975-1989.	7.2	21
222	Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Haematologica, 2015, 100, e237-e239.	3.5	21
223	Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. European Journal of Clinical Investigation, 2016, 46, 392-397.	3.4	21
224	Aldolase B mutations in Italian families affected by hereditary fructose intolerance.. Journal of Medical Genetics, 1991, 28, 241-243.	3.2	20
225	Cloning and Characterization ofRNF6,a Novel RING Finger Gene Mapping to 13q12. Genomics, 1999, 58, 94-97.	2.9	20
226	Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript. Leukemia, 2005, 19, 1096-1099.	7.2	20
227	Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling. Leukemia, 2014, 28, 2106-2109.	7.2	20
228	Megalencephaly Syndromes: Exome Pipeline Strategies for Detecting Low-Level Mosaic Mutations. PLoS ONE, 2014, 9, e86940.	2.5	20
229	Null alleles of the aldolase B gene in patients with hereditary fructose intolerance.. Journal of Medical Genetics, 1994, 31, 499-503.	3.2	18
230	APPROPRIATE CONTROLS FOR REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RTâ€PCR). British Journal of Haematology, 1994, 87, 218-218.	2.5	18
231	BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-Î±. British Journal of Haematology, 1998, 102, 1271-1278.	2.5	18
232	Realâ€world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. British Journal of Haematology, 2021, 192, 62-74.	2.5	18
233	A novel arrangement of sequence elements surrounding the rDNA promoter and its spacer duplications in tsetse species. Journal of Molecular Biology, 1987, 195, 63-74.	4.2	17
234	Evaluation of JAK2^{V617F} in B and T Cell Neoplasms: Identification of JAK2^{V617F} Mutation of Undetermined Significance (JMUS) in the Bone Marrow of Three Individuals. Acta Haematologica, 2007, 118, 209-214.	1.4	17

#	Article	IF	Citations
235	Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals. Leukemia, 2015, 29, 1600-1602.	7.2	16
236	Measurement ofBCR-ABL1by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme. British Journal of Haematology, 2017, 177, 414-422.	2.5	16
237	The European LeukemiaNet: achievements and perspectives. Haematologica, 2011, 96, 156-162.	3.5	15
238	Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex-mismatched BMT: recovery of donor-type haemopoiesis predicted by non-isotopic in situ hybridization (ISH). British Journal of Haematology, 1994, 88, 400-402.	2.5	14
239	Acquired Uniparental Disomy in Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2012, 26, 981-991.	2.2	14
240	Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. Haematologica, 2007, 92, 1153-1158.	3.5	14
241	Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1. Leukemia, 2009, 23, 358-364.	7.2	13
242	Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus. Leukemia, 2015, 29, 2069-2074.	7.2	13
243	Hereditary fructose intolerance. International Journal of Biochemistry & Cell Biology, 1990, 22, 685-689.	0.5	12
244	Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia. British Journal of Haematology, 2004, 126, 508-511.	2.5	12
245	Chronic myeloid leukemia â€“ some topical issues. Leukemia, 2007, 21, 1347-1352.	7.2	12
246	No evidence for increased prevalence of JAK2 V617F in women with a history of recurrent miscarriage. British Journal of Haematology, 2009, 144, 802-803.	2.5	12
247	Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators. Leukemia, 2016, 30, 2258-2260.	7.2	12
248	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. American Journal of Human Genetics, 2021, 108, 284-294.	6.2	12
249	Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia. International Journal of Hematology, 2008, 88, 197-201.	1.6	11
250	Acute myeloid leukaemia with associated eosinophilia: justification for FIP1L1â€PDGFRA screening in cases lacking the CBFBâ€MYH11 fusion gene. British Journal of Haematology, 2009, 146, 225-227.	2.5	11
251	Interlaboratory Diagnostic Validation of Conformation-Sensitive Capillary Electrophoresis for Mutation Scanning. Clinical Chemistry, 2010, 56, 593-602.	3.2	11
252	Consensus on <scp>BCR</scp>â€<scp>ABL</scp>1 reporting in chronic myeloid leukaemia in the <scp>UK</scp>. British Journal of Haematology, 2018, 182, 777-788.	2.5	11

#	Article	IF	Citations
253	PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasia. Leukemia, 2019, 33, 1184-1194.	7.2	11
254	Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells. British Journal of Cancer, 1998, 78, 601-605.	6.4	10
255	Assignment of the Steroid Receptor Coactivator-1 (SRC-1) Gene to Human Chromosome Band 2p23. Genomics, 1998, 52, 242-244.	2.9	10
256	Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases. Clinical Science, 2006, 111, 233-249.	4.3	10
257	Recurrent CEP85Lâ€“PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia. Leukemia and Lymphoma, 2013, 54, 1527-1531.	1.3	10
258	Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia, 2022, 36, 1834-1842.	7.2	10
259	Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. Haematologica, 2013, 98, 576-583.	3.5	9
260	Antisense Oligonucleotides Modulating Activation of a Nonsense-Mediated RNA Decay Switch Exon in the ATM Gene. Nucleic Acid Therapeutics, 2016, 26, 392-400.	3.6	9
261	Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1225-1233.	2.5	9
262	Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis. International Journal of Molecular Sciences, 2021, 22, 2562.	4.1	9
263	Mutations of the transcription factor AML1/CBA2 are uncommon in blastic transformation of chronic myeloid leukaemia. Leukemia, 2001, 15, 476-477.	7.2	8
264	Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia, 2020, 34, 3206-3214.	7.2	8
265	The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders. British Journal of Haematology, 2021, 195, 338-351.	2.5	8
266	Assignment<footref rid="foot01">¹</footref> of ZNF262 to human chromosome band 1p34â†’p32 by in situ hybridization. Cytogenetic and Genome Research, 1999, 85, 306-307.	1.1	7
267	A case of myelofibrosis with a t(4;13)(q25;q12): evidence for involvement of a second 13q12 locus in chronic myeloproliferative disorders. British Journal of Haematology, 1999, 105, 771-774.	2.5	7
268	Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia. Leukemia, 2020, 34, 2279-2284.	7.2	7
269	Paucimorphic Alleles versus Polymorphic Alleles and Rare Mutations in Disease Causation: Theory, Observation and Detection. Current Genomics, 2004, 5, 431-438.	1.6	7
270	The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. Annals of Hematology, 2011, 90, 365-366.	1.8	6

#	Article	IF	Citations
271	Cloning of ZNF237, a novel member of the MYM gene family that maps to human chromosome 13q11â†'q12. Cytogenetic and Genome Research, 2000, 89, 24-28.	1.1	5
272	Exon-centric regulation of ATM expression is population-dependent and amenable to antisense modification by pseudoexon targeting. Scientific Reports, 2016, 6, 18741.	3.3	5
273	A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5). Acta Haematologica, 2017, 138, 198-200.	1.4	5
274	Routine Screening for <i>KIT</i> M541L Is Not Warranted in the Diagnostic Work-Up of Patients with Hypereosinophilia. Acta Haematologica, 2018, 139, 71-73.	1.4	5
275	A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature. Acta Haematologica, 2019, 142, 105-112.	1.4	5
276	Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder. Bone Marrow Transplantation, 2009, 44, 197-199.	2.4	4
277	Philadelphia Chromosome-Negative Myeloproliferative Neoplasm With a Novel Platelet-Derived Growth Factor Receptor-Î² Rearrangement Responsive to Imatinib. Journal of Clinical Oncology, 2012, 30, e109-e111.	1.6	4
278	Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms?. Leukemia, 2013, 27, 1930-1932.	7.2	4
279	No association between myeloproliferative neoplasms and the Crohn's disease-associated STAT3 predisposition SNP rs744166. Haematologica, 2010, 95, 1226-1227.	3.5	3
280	Neutrophilic leukemoid reaction in multiple myeloma. American Journal of Hematology, 2015, 90, 1090-1090.	4.1	3
281	Absence of <i>CALR</i> Mutations in Idiopathic Erythrocytosis Patients with Low Serum Erythropoietin Levels. Acta Haematologica, 2018, 139, 217-219.	1.4	3
282	An extremely delayed cytogenetic response to interferon-Î± in a patient with chronic myeloid leukaemia. Leukemia, 1997, 11, 614-616.	7.2	2
283	The t(4;9)(q11;q33) fuses CEP110 to KIT in a case of acute myeloid leukemia. Leukemia, 2011, 25, 1049-1050.	7.2	2
284	Chronic Eosinophilic Leukaemia Associated with <i>JAK2</i> Exon 13 Insertion/Deletion Mutations. Acta Haematologica, 2022, 145, 201-206.	1.4	2
285	HGNC nomenclature for fusion genes. Leukemia, 2021, 35, 3039-3039.	7.2	1
286	Non-random involvement of chromosome 13 in patients with persistent or relapsed disease after bone-marrow transplantation for chronic myeloid leukemia. Genes Chromosomes and Cancer, 2000, 27, 278.	2.8	1